



CELLENION

One line pitch:

Cellenion is specialised in controlled cell dispensing technologies with applications in the fields of bioprinting and single-cell dispensing.

Market Analysis:

Cellenion's activities and future products are all addressed at highly promising life science markets that are showing consistent and significant growth: Bioprinting market is still in its infancy but predicted to grow with 17% CAGR to 6.12 billion \$ in 2022 (Statistics MRC Report, May 2016). mAb market size: 75 billion \$ in 2015 with 15% CAGR for next 5 years (BioProcess Technology Consultants, January 2015). Single-cell analysis market size: 1.45 Billion \$ in 2016 with 18.2% CAGR for next 5 years (MarketsandMarkets Report, April 2016).

Value proposition:

Cellenion: Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of bioprinting and single-cell isolation: Bioprinting is the process of generating spatially-controlled cell patterns using 3D printing technologies. Cellenion will aim toward both miniaturization and automation in order to produce reproducible models of different complexities. Ability to manipulate single-cell has long been a challenge for the scientific community due to their micrometric size and delicate nature. Cellenion has developed and patented the CellenONE technology that allows high throughput isolation and dispensing of single-cell.

Business Model:

CellenONE (Equipment and consumable) Cellenion is currently developing an integrated system and its associated consumables to perform automated single-cell isolation. This compact device performs gentle single-cell isolation with unseen precision. It will be commercialised in early 2017. Services for bioprinting In the field of bioprinting, Cellenion offer a service of 3D in vitro models printing and development. We are currently collaborating with a range of companies to develop novel 3D cellular models or optimise existing one. In this field, we are open to contracted research contracts or co-developments. In parallel, Cellenion has an R&D program to develop and commercialise its own models.

IP and Regulatory situation:

Cellenion currently hold an exclusive licence for the use of SCIENION dispensing technologies and solutions (including the licence to the CellenONE Technology) applied to the field of cell dispensing and its applications. In the future, novel IP will be own directly by Cellenion. Cellenion and CellenONE were filed for European Trademark registration at the beginning of August 2016.

COMPANY PROFILE

- **Website:**
Under construction
- **Field:**
- **Contact:**
TOURNIAIRE Guilhem
gtourniaire@scienion.com
- **Location:**
60 Avenue Rockefeller Bioparc
Laennec
69008 Lyon
France
- **Founded in:** //05/2016
- **Employees:** 3
- **Financial information (€):**
 - **Company stage:**
Proof Of Concept
 - **Capital raised to date:**
NA
 - **Monthly burn rate:**
20000
 - **Capital seeking and date:**
4500000 in Q4 2017
- **Investors:**
SCIENION AG